BRPI0913374A2 - muteínas fviii para tratamento de doença de von willebrand - Google Patents

muteínas fviii para tratamento de doença de von willebrand

Info

Publication number
BRPI0913374A2
BRPI0913374A2 BRPI0913374A BRPI0913374A BRPI0913374A2 BR PI0913374 A2 BRPI0913374 A2 BR PI0913374A2 BR PI0913374 A BRPI0913374 A BR PI0913374A BR PI0913374 A BRPI0913374 A BR PI0913374A BR PI0913374 A2 BRPI0913374 A2 BR PI0913374A2
Authority
BR
Brazil
Prior art keywords
treatment
von willebrand
willebrand disease
fviii muteins
fviii
Prior art date
Application number
BRPI0913374A
Other languages
English (en)
Inventor
Glenn Pierce
Haiyan Jung
John E Murphy
Junliang Pan
Tongyao Liu
Xin Zhang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BRPI0913374A2 publication Critical patent/BRPI0913374A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0913374A 2008-06-04 2009-06-04 muteínas fviii para tratamento de doença de von willebrand BRPI0913374A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5879508P 2008-06-04 2008-06-04
PCT/US2009/046327 WO2009149303A1 (en) 2008-06-04 2009-06-04 Fviii muteins for treatment of von willebrand disease

Publications (1)

Publication Number Publication Date
BRPI0913374A2 true BRPI0913374A2 (pt) 2015-11-24

Family

ID=41398537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913374A BRPI0913374A2 (pt) 2008-06-04 2009-06-04 muteínas fviii para tratamento de doença de von willebrand

Country Status (12)

Country Link
US (1) US20110286988A1 (pt)
EP (1) EP2297330A4 (pt)
JP (1) JP5674650B2 (pt)
KR (1) KR20110017420A (pt)
CN (1) CN102112623A (pt)
AU (1) AU2009256093A1 (pt)
BR (1) BRPI0913374A2 (pt)
CA (1) CA2726942A1 (pt)
IL (1) IL209719A0 (pt)
MX (1) MX2010013219A (pt)
WO (1) WO2009149303A1 (pt)
ZA (1) ZA201008720B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
EA038705B1 (ru) * 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
LT3013855T (lt) * 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1379271A1 (en) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Method for treating von willebrand's disease
AU2003227687B2 (en) * 2002-04-29 2009-10-15 Stichting Sanquin Bloedvoorziening Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio

Also Published As

Publication number Publication date
JP2011523663A (ja) 2011-08-18
CA2726942A1 (en) 2009-12-10
WO2009149303A1 (en) 2009-12-10
IL209719A0 (en) 2011-02-28
EP2297330A4 (en) 2012-03-14
US20110286988A1 (en) 2011-11-24
JP5674650B2 (ja) 2015-02-25
CN102112623A (zh) 2011-06-29
ZA201008720B (en) 2012-02-29
AU2009256093A1 (en) 2009-12-10
KR20110017420A (ko) 2011-02-21
EP2297330A1 (en) 2011-03-23
MX2010013219A (es) 2011-04-11

Similar Documents

Publication Publication Date Title
BRPI0913374A2 (pt) muteínas fviii para tratamento de doença de von willebrand
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
HUE058231T2 (hu) Eszköz gastrooesophagealis reflux betegség kezelésére
DK2222272T3 (da) Behandling af luftvejssygdom
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BRPI0911923A2 (pt) dispositivos filamentosos para o tratamento de defeitos vasculares
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
EP2390555A4 (en) LIGHTING UNIT
BRPI0911780A8 (pt) compostos peguilados de hormônio de crescimento humano recombinante
BRPI0916931A2 (pt) agentes terapêuticos
EP2527729A4 (en) ILLUMINATION DEVICE
ITCO20080005A1 (it) "shaker monouso"
PL2621523T3 (pl) Sposoby leczenia choroby autoimmunologicznej z zastosowaniem biokompatybilnych bioabsorbowalnych nanosfer
EP2525630A4 (en) ILLUMINATION DEVICE
EP2712540A4 (en) LIGHTING STRUCTURE AND ENDOSCOPE
BR112012025270A2 (pt) "composição de cuidados pessoais"
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
EP3381471C0 (en) PAIN TREATMENT
BRPI0812250A2 (pt) Composição farmacêutica de liberação lenta feita de micropartículas
ES2399651T8 (es) Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI0912043A2 (pt) métodos de tratamento de doença associada à cinesina meiótica
DK2175849T3 (da) Behandling af melanomer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.